Thrivent Financial for Lutherans
VOR icon

Thrivent Financial for Lutherans’s Vor Biopharma VOR Stock Holding History

Thrivent Financial for Lutherans’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-7,485
Closed -$317K – 2550
2023
Q3 		$317K Sell
7,485
-8,148
-52% -$442K ﹤0.01% 2296
2023
Q2 		$967K Sell
15,633
-127
-0.8% -$11.6K ﹤0.01% 1826
2023
Q1 		$1.7M Buy
15,760
+419
+3% +$46.4K ﹤0.01% 1408
2022
Q4 		$2.04M Buy
15,341
+220
+1% +$21.8K 0.01% 1246
2022
Q3 		$1.2M Buy
15,121
+778
+5% +$76.5K ﹤0.01% 1556
2022
Q2 		$1.43M Sell
14,343
-948
-6% -$97K ﹤0.01% 1462
2022
Q1 		$1.85M Sell
15,291
-16
-0.1% -$2.72K ﹤0.01% 1382
2021
Q4 		$3.56M Buy
15,307
+117
+0.8% +$33.7K 0.01% 1045
2021
Q3 		$4.76M Buy
15,190
+1,266
+9% +$376K 0.01% 909
2021
Q2 		$5.19M Buy
13,924
+35
+0.3% +$17.3K 0.01% 906
2021
Q1 		$12M Buy
+13,889
New +$11.8M 0.03% 606

Other funds holding VOR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Thrivent Financial for Lutherans's VOR Position: Q4 2023 in Review

Thrivent Financial for Lutherans sold out of Vor Biopharma (VOR) in Q4 2023, closing a stake of 7,485 shares — an estimated $317K sold.

Thrivent Financial for Lutherans first reported a position in VOR in Q1 2021 and held it in 11 quarters. The position peaked at $12M in Q1 2021. 60 funds tracked by Wall St. Rank hold VOR as of Q4 2023.

  • Thrivent Financial for Lutherans reported no remaining Vor Biopharma position as of Q4 2023 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 7,485 Vor Biopharma shares in Q4 2023, an estimated $317K.
  • Thrivent Financial for Lutherans first reported a position in Vor Biopharma in Q1 2021 and held it in 11 quarters.
  • Thrivent Financial for Lutherans's Vor Biopharma position peaked at $12M in Q1 2021.
  • 60 funds tracked by Wall St. Rank held Vor Biopharma as of Q4 2023.

Based on Thrivent Financial for Lutherans's 13F filing for Q4 2023, filed 14 Feb 2024.